Erythroferrone and Its Impact on Maternal and Neonatal Iron Homeostasis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 338
- 试验地点
- 2
- 主要终点
- Neonatal Erythroferrone at Birth
研究概览
简要总结
Erythroferrone (ERFE) is a recently identified iron-regulatory hormone that couples iron homeostasis to erythropoiesis but at this time there are no human data on this hormone in pregnant women and their neonates. The investigators hypothesize that ERFE is a sensitive biomarker of iron deficiency and anemia in pregnancy and neonates, and that it mediates the feedback mechanism to correct iron deficiency and anemia. To address this research gap, the investigators will measure ERFE in maternal serum, umbilical cord serum and placental tissue using an existing biospecimen archive.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 11 Years 至 45 Years（Child, Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy pregnant volunteers
排除标准
- •Hemoglobinopathies
- •Pre-existing diabetes
- •Malabsorption diseases
- •Pregnancy induced hypertension
- •Elevated diastolic blood pressure (>110)
- •Previous treatment for lead exposure or elevated childhood lead concentrations.
- •Preexisting medical conditions known to impact iron homeostasis
结局指标
主要结局
Neonatal Erythroferrone at Birth
时间窗: Measures will be obtained from umbilical cord blood collected at delivery
Maternal Erythroferrone During Pregnancy
时间窗: Measures will be obtained from maternal blood collected throughout the 40 weeks of pregnancy
Maternal Erythroferrone at Delivery
时间窗: Measures will be obtained from maternal blood collected at delivery
Placental Erythroferrone mRNA and Ferroportin protein Expression
时间窗: Measures will be obtained from placental samples collected at delivery
次要结局
未报告次要终点